secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-06-15T20:12:31+00:00
Accession:  0001790340-26-000074
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering appoints Andrew Gengos as CFO, effective July 16, 2026
------------------------------------------------------------------

- Andrew Gengos named CFO and Treasurer, replacing Mallory Morales who remains SVP Finance, CAO.
- Gengos gets base salary of $530,000 and target bonus of 40% of base salary.
- Inducement grant of 650,000 stock options under 2025 Employment Inducement Award Plan.
- Gengos previously CFO at Terns Pharmaceuticals (Feb 2025-May 2026) and CFO/CBO at LeonaBio.
- Gengos' employment includes severance provisions: 12 months salary plus COBRA on qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/0001790340-26-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/imrx-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer